Here are three major retailers that have closed Glasgow stores this year
As we reach the halfway mark of 2025, we've put together a list of several major retailers that have closed down or are closing down their stores in Glasgow.
Brands, including Superdry and Michael Kors, are among some of the retail giants to have shut down their shops in and around the city already.
Meanwhile, other retailers, including Scotts, have announced they are set to close down stores in the city.
Here are three beloved retailers which have closed down their stores across the city, and two which are set to shut down their stores:
READ MORE: Major retailer suddenly closed down Glasgow Silverburn store
READ MORE: Global retailer suddenly closed down Braehead storeSuperdry's former store in Silverburn Shopping Centre, Glasgow (Image: Newsquest) One major clothing retailer recently closed down one of its shops in Glasgow's Silverburn Shopping Centre, and another one of its branches in Brahead Shopping Centre in Renfrew, Renfrewshire.
On June 9, we reported how Superdry had shut down its Silverburn store. A sign on the venue's window revealed the devastating news.
It said: "This store is now closed. You can continue to shop the full collection at Superdry.com."
Braehead Shopping Centre, Renfrew (Image: Newsquest) Meanwhile, on June 10, we revealed how the global retailer had also shut its shop in Braehead, near Glasgow.
A spokesperson for the leisure facility confirmed the news to the Glasgow Times.
In a statement, they said: 'Superdry is leaving Braehead Shopping Centre and we wish the staff well for the future."
READ MORE: Popular retailer announced closure of Glasgow Fort storeClosing down sign on Tessuti (left), image of Glasgow Fort (right) (Image: Newsquest) Another retailer which is set to close down its store at Glasgow's Fort is Tessuti.
The established and popular clothing seller will be closing its shop at the East End shopping complex.
Signage appeared on the store's window recently, confirming the sad news. It read: "Closing down. Up to 70 per cent off."
It is unclear when the store will be closing down.
READ MORE: Retail giant announced shock closure of Glasgow Fort storeClosing down sign on Scotts store at Glasgow Fort (Image: Newsquest) On top of Tessuti, another big retailer announced it would be closing down its store at Glasgow's Fort as well.
On June 9, we reported that the retail giant Scotts revealed the shock closure of its store at the centre.
A sign was placed on the shop's window confirming the news; however, it is unclear when the store will close its doors.
READ MORE: World-renowned retailer suddenly 'closed' Glasgow store
READ MORE: Global retailer speaks out after closure of Glasgow storeMichael Kors former shop on Glasgow's Buchanan Street (Image: Newsquest) In April, we reported how a world-renowned fashion brand mysteriously shut down its shop in Glasgow city centre.
Michael Kors, known for its luxury handbags, shut its shop on Buchanan Street.
Following its shock closure, the retailer told the Glasgow Times that its store on the Style Mile was 'currently closed'.Size? former store in Glasgow city centre (Image: Newsquest)
READ MORE: Mystery as popular Glasgow store suddenly 'closes down'
In January, popular streetwear retailer size? suddenly closed its Glasgow city centre store.
The brand pulled down the shutters on its shop on Royal Exchange Square on Saturday, January 18.
It was never revealed why the retailer decided to close down its city centre store.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
6 hours ago
- Yahoo
SNP must follow Labour's plans after UK Government winter fuel U-turn, says MSP
Readers may be aware of the welcome news from the UK Labour Government on Winter Fuel Payments for older people this week. The move means that more than three quarters of pensioners in England and Wales will receive the payment this winter. Households with a pensioner under 80 years old will receive £200, while those with one over 80 will receive £300. But by restricting it to those with an income of, or below, £35,000 per year, the UK Labour Government is also making sure that rich millionaires who simply don't need the payment won't get it. Pensioners in England and Wales with incomes of, or below, £35,000 a year will receive winter fuel payments after a U-turn by the UK Government - and Neil Bibby says the Scottish Government will have no choice but to follow suit for older people north of the border. (Image: Newsquest) This is a response to the many concerns raised that the threshold for eligibility was too low. It's not often governments listen and make changes when they get things wrong, but it is refreshing, and I am glad they have. This news is fantastic for pensioners south of the border who were worried about heating their homes this winter. But it is also great news for pensioners in Scotland because the SNP Government will now have no choice but to follow suit. This decision will bring even more money to Scotland - so there is no excuse not to pass it on. READ MORE: Inverclyde councillors rubber-stamp £600,000 fuel help to more than 1,000 needy pensioners The SNP Government also needs to follow Labour's plan because, since the payment was devolved in Scotland, many lower- and middle-income Scottish pensioners are due to get less money than they would elsewhere in the UK. The SNP's current plans mean that Scottish pensioners who are not in receipt of specific benefits will only receive £100. Since the UK Government's initial announcement on the Winter Fuel Payment last year, Scottish Labour has continued to call for a Scottish solution to the issue. READ MORE: 12,500 households in Inverclyde set to lose up to £300 to help keep warm this winter Indeed, Scottish Labour leader Anas Sarwar stated last November that he would reinstate the payment and extend the eligibility threshold if elected into government in 2026. The UK Labour government's expansion of the Winter Fuel Payment is a game-changer and good news for pensioners. The SNP Scottish Government should now follow suit without delay to ensure that pensioners in Scotland get the benefit.
Yahoo
7 hours ago
- Yahoo
Intellia Therapeutics Announces Positive Three-Year Data from Phase 1 Trial of Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema (HAE) at the European Academy of Allergy and Clinical Immunology Congress
With up to three years of follow-up, a single dose of lonvo-z led to a 98% mean reduction in monthly HAE attack rate in all 10 patients All 10 patients were attack-free and treatment-free for a median of 23 months through the latest follow-up, demonstrating the potential of lonvo-z to become the first one-time therapy for most HAE patients Lonvo-z was well tolerated and continues to demonstrate a favorable safety profile The global Phase 3 HAELO trial of lonvo-z has concluded screening ahead of schedule with more than half screened from U.S. sites; Intellia to provide an update on enrollment in the future CAMBRIDGE, Mass., June 15, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced three-year follow-up data from the Phase 1 portion of the ongoing Phase 1/2 study in patients with HAE after receiving a single dose of lonvoguran ziclumeran (lonvo-z, also known as NTLA-2002). Results were shared in an oral presentation at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2025, held June 13-16 in Glasgow, United Kingdom. 'Today's results underscore the promising potential of Intellia's approach to gene editing therapy – a one-time treatment that was well tolerated and offered a highly differentiated, durable effect for patients suffering from a serious disease,' said Intellia President and Chief Executive Officer John Leonard, M.D. 'Seeing all 10 patients in the Phase 1 portion of this study free from both HAE attacks and chronic therapy at nearly two years of median follow-up is incredibly encouraging. These data fuel our optimism for the outcomes of our ongoing Phase 3 HAELO study, which we expect to report in the first half of 2026, and highlight the strong value we believe it will offer patients, physicians and payers.' 'People living with HAE often report a reduced quality of life because they worry about the likelihood of their next attack, either because they still experience attacks or are reminded of it by their use of chronic therapy,' said Dr. Joshua Jacobs, Medical Director, Allergy and Asthma Clinical Research, Inc. 'Based on the data, it is reasonable to expect lonvo-z could offer patients the potential to be free from both physical HAE attacks and the burden of managing chronic HAE treatment.' In the Phase 1 portion of the study, a one-time dose of 25 mg (N=3), 50 mg (N=4) or 75 mg (N=3) of lonvo-z was administered via intravenous infusion and plasma kallikrein protein levels were measured along with HAE attacks. At the time of the February 12 data cutoff, patients were attack-free and treatment-free for a median of nearly two years. With up to three years of follow-up, a single dose of lonvo-z led to a mean reduction in monthly HAE attack rate of 98% over the study period, compared to pre-treatment baseline. For all 10 patients, deep, dose-dependent and durable reductions in plasma kallikrein protein continued to be observed through the latest assessment. Safety Across all three dose levels, lonvo-z has been well tolerated and continues to demonstrate a favorable safety profile consistent with earlier data presented at EAACI in 2024. The most frequent adverse events during the study period were infusion-related reactions (IRRs). IRRs were mostly Grade 1 and resolved with all patients receiving the full dose. With up to 3 years of follow-up, no treatment-emergent serious adverse events were observed, and no treatment-related adverse events were observed during the period following 28 days after dosing. Clinical Development PlansIntellia's global Phase 3, randomized, double-blind, placebo-controlled HAELO trial is ongoing to assess the safety and efficacy of lonvo-z at the 50 mg dosage. The Company announced today the HAELO trial has successfully completed screening ahead of schedule, with over half of the patients being screened in the United States. The study is no longer recruiting and Intellia will provide an update on enrollment in the future. New and longer-term data from the Phase 2 portion of the ongoing Phase 1/2 study is planned to be presented in the second half of 2025. Intellia expects to submit a biologics license application (BLA) in 2026 to support the Company's plans for a U.S. launch in 2027. For more information on HAELO (NCT06634420), please visit About the Lonvoguran Ziclumeran (lonvo-z, also known as NTLA-2002) Clinical ProgramIntellia's ongoing Phase 1/2 study is evaluating the safety and efficacy of lonvo-z in adults with Type I or Type II hereditary angioedema (HAE). The Phase 1 portion of the study is an international, open-label study designed to identify the dose level of lonvo-z selected for further evaluation in the Phase 2 portion of the study. Enrollment in both portions of the Phase 1/2 study is complete. Intellia dosed the first patient in the global Phase 3, randomized, double-blind, placebo-controlled HAELO trial in January of 2025. Visit (NCT05120830) for more details. About Lonvo-zBased on Nobel Prize-winning CRISPR/Cas9 technology, lonvo-z has the potential to become the first one-time treatment for hereditary angioedema (HAE). Lonvo-z is an investigational in vivo CRISPR-based gene editing therapy designed to prevent HAE attacks by inactivating the kallikrein B1 (KLKB1) gene, which encodes for prekallikrein, the kallikrein precursor protein. Interim Phase 1/2 clinical data showed dramatic reductions in attack rate, as well as consistent, deep and durable reductions in kallikrein levels. Lonvo-z has received five notable regulatory designations, including Orphan Drug and RMAT Designation by the U.S. Food and Drug Administration (FDA), the Innovation Passport by the U.K. Medicines and Healthcare products Regulatory Agency (MHRA), Priority Medicines (PRIME) Designation by the European Medicines Agency, as well as Orphan Drug Designation (ODD) by the European Commission. About Intellia TherapeuticsIntellia Therapeutics, Inc. (NASDAQ:NTLA) is a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies. Since its inception, Intellia has focused on leveraging gene editing technology to develop novel, first-in-class medicines that address important unmet medical needs and advance the treatment paradigm for patients. Intellia's deep scientific, technical and clinical development experience, along with its people, is helping set the standard for a new class of medicine. To harness the full potential of gene editing, Intellia continues to expand the capabilities of its CRISPR-based platform with novel editing and delivery technologies. Learn more at and follow us @intelliatx. Forward-Looking Statements This press release contains 'forward-looking statements' of Intellia Therapeutics, Inc. ('Intellia' or the 'Company') within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, express or implied statements regarding Intellia's beliefs and expectations concerning: the safety, efficacy, success and advancement of its clinical programs for lonvoguran ziclumeran or 'lonvo-z' (also known as NTLA-2002) for hereditary angioedema ('HAE'), including the ability to successfully complete its global Phase 3 HAELO study; its expectation to present additional data regarding lonvo-z, including reporting outcomes of the Phase 3 HAELO study in the first half of 2026 and presenting new and longer-term data from the Phase 2 portion of the ongoing Phase 1/2 study of lonvo-z in the second half of 2025; and its expectation to be able to support a biologics license application for lonvo-z for the treatment of HAE by 2026 for a U.S. launch in 2027. Any forward-looking statements in this press release are based on management's current expectations and beliefs of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: risks related to Intellia's ability to protect and maintain its intellectual property position; risks related to Intellia's relationship with third parties, including its contract manufacturers, licensors and licensees; risks related to the ability of its licensors to protect and maintain their intellectual property position; risks related to Intellia's ability to protect and maintain its intellectual property position; risks related to valid third party intellectual property; risks related to Intellia's relationship with third parties, including its licensors and licensees; risks related to the ability of its licensors to protect and maintain their intellectual property position; uncertainties related to regulatory agencies' evaluation of regulatory filings and other information related to our product candidates, including lonvo-z; uncertainties related to the authorization, initiation and conduct of studies and other development requirements for our product candidates, including uncertainties related to regulatory approvals to conduct clinical trials, including our ability to complete the Phase 3 HAELO study for HAE; the risk that any one or more of Intellia's product candidates, including lonvo-z, will not be successfully developed and commercialized; and the risk that the results of preclinical studies or clinical studies will not be predictive of future results in connection with future studies for the same product candidate or Intellia's other product candidates. For a discussion of these and other risks and uncertainties, and other important factors, any of which could cause Intellia's actual results to differ from those contained in the forward-looking statements, see the section entitled 'Risk Factors' in Intellia's most recent annual report of Form 10-K and quarterly report on Form 10-Q, as well as discussions of potential risks, uncertainties, and other important factors in Intellia's other filings with the Securities and Exchange Commission. All information in this press release is as of the date of the release, and Intellia undertakes no duty to update this information unless required by ChavesSenior Manager, Investor Media:Matt CrensonTen Bridge Communicationsmcrenson@
Yahoo
7 hours ago
- Yahoo
Here are three major retailers that have closed Glasgow stores this year
As we reach the halfway mark of 2025, we've put together a list of several major retailers that have closed down or are closing down their stores in Glasgow. Brands, including Superdry and Michael Kors, are among some of the retail giants to have shut down their shops in and around the city already. Meanwhile, other retailers, including Scotts, have announced they are set to close down stores in the city. Here are three beloved retailers which have closed down their stores across the city, and two which are set to shut down their stores: READ MORE: Major retailer suddenly closed down Glasgow Silverburn store READ MORE: Global retailer suddenly closed down Braehead storeSuperdry's former store in Silverburn Shopping Centre, Glasgow (Image: Newsquest) One major clothing retailer recently closed down one of its shops in Glasgow's Silverburn Shopping Centre, and another one of its branches in Brahead Shopping Centre in Renfrew, Renfrewshire. On June 9, we reported how Superdry had shut down its Silverburn store. A sign on the venue's window revealed the devastating news. It said: "This store is now closed. You can continue to shop the full collection at Braehead Shopping Centre, Renfrew (Image: Newsquest) Meanwhile, on June 10, we revealed how the global retailer had also shut its shop in Braehead, near Glasgow. A spokesperson for the leisure facility confirmed the news to the Glasgow Times. In a statement, they said: 'Superdry is leaving Braehead Shopping Centre and we wish the staff well for the future." READ MORE: Popular retailer announced closure of Glasgow Fort storeClosing down sign on Tessuti (left), image of Glasgow Fort (right) (Image: Newsquest) Another retailer which is set to close down its store at Glasgow's Fort is Tessuti. The established and popular clothing seller will be closing its shop at the East End shopping complex. Signage appeared on the store's window recently, confirming the sad news. It read: "Closing down. Up to 70 per cent off." It is unclear when the store will be closing down. READ MORE: Retail giant announced shock closure of Glasgow Fort storeClosing down sign on Scotts store at Glasgow Fort (Image: Newsquest) On top of Tessuti, another big retailer announced it would be closing down its store at Glasgow's Fort as well. On June 9, we reported that the retail giant Scotts revealed the shock closure of its store at the centre. A sign was placed on the shop's window confirming the news; however, it is unclear when the store will close its doors. READ MORE: World-renowned retailer suddenly 'closed' Glasgow store READ MORE: Global retailer speaks out after closure of Glasgow storeMichael Kors former shop on Glasgow's Buchanan Street (Image: Newsquest) In April, we reported how a world-renowned fashion brand mysteriously shut down its shop in Glasgow city centre. Michael Kors, known for its luxury handbags, shut its shop on Buchanan Street. Following its shock closure, the retailer told the Glasgow Times that its store on the Style Mile was 'currently closed'.Size? former store in Glasgow city centre (Image: Newsquest) READ MORE: Mystery as popular Glasgow store suddenly 'closes down' In January, popular streetwear retailer size? suddenly closed its Glasgow city centre store. The brand pulled down the shutters on its shop on Royal Exchange Square on Saturday, January 18. It was never revealed why the retailer decided to close down its city centre store.
